Clinical Trials Browser

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06319820 2026-05-08

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06661720 2026-05-08

STRIKE

Phase 3 Recruiting

1,040 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06919965 2026-05-08

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06931340 2026-05-08

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Phase 3 Recruiting

1,260 enrolled

Genitourinary

Prostatic Neoplasms

NCT07164443 2026-05-08

KLK2-comPAS

Phase 3 Recruiting

663 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07548164 2026-05-08

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Phase 3 Recruiting

224 enrolled

Genitourinary

Prostatic Neoplasms

NCT04134260 2026-05-07

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

586 enrolled

Genitourinary

Prostatic Neoplasms

NCT05946213 2026-05-07

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

1,209 enrolled

Genitourinary

Prostatic Neoplasms

NCT03819101 2026-05-06

PEACE-4

Phase 3 Recruiting

1,210 enrolled

Genitourinary

Prostatic Neoplasms

NCT06764485 2026-05-06

rechARge

Phase 3 Recruiting

960 enrolled

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06136624 2026-05-05

OMAHA-003

Phase 3 Recruiting

1,310 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT06401330 2026-05-05

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Phase 3 Recruiting

1,656 enrolled

Genitourinary

Stage I Mixed Cell Type Kidney Wilms Tumor

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

736 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06500455 2026-05-04

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Phase 3 Recruiting

269 enrolled

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

70 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04916613 2026-04-28

GETUG-AFU 40

Phase 3 Recruiting

300 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06857175 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Phase 3 Recruiting

508 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06439225 2026-04-16

OPTION-DDR

Phase 3 Recruiting

236 enrolled

Genitourinary

Prostatic Neoplasms

NCT06122584 2026-04-14

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Phase 3 Recruiting

380 enrolled

Genitourinary

Prostatic Neoplasms

NCT06235697 2026-04-14

ASCENDE-SBRT

Phase 3 Recruiting

710 enrolled

Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06235151 2026-04-08

Solar-Stage

Phase 3 Recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

PSMA-DC

MK-5684-004

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

MK-6482-043

LITESPARK-034

ABLE-32

ABLE-22

MK-2400-001

A Study of Changes to Prostate Procedures

MEVPRO-3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

FORAGER-2

TroFuse-031

ROPES

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

EvoPAR-PR02

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

CLARIFY

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

LITESPARK-033

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

KLK2-PASenger

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

EV-309

MoonRISe-1

STRIKE

MoonRISe-3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

KLK2-comPAS

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

PEACE-4

rechARge

OMAHA-003

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

GETUG-AFU 40

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

OPTION-DDR

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

ASCENDE-SBRT

TRIPLE-SWITCH

Solar-Stage